Ricerca avanzata

Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4) > Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4):429-34

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOGIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

 

Giornale Italiano di Dermatologia e Venereologia 2015 Agosto;150(4):429-34

NON-MELANOMA SKIN CANCER 

Topical and systemic medical treatments of basal cell carcinoma

Sollena P. 1, Del Regno L. 1, Fargnoli M. C. 2, Peris K. 1

1 Department of Dermatology, Sacro Cuore Catholic University of Rome, Rome, Italy;
2 Department of Dermatology, University of L’Aquila, L’Aquila, Italy

Basal cell carcinoma (BCC) is the most common non melanoma skin cancer (NMSC) in white individuals over the age of 40 years. BCCs usually grow slowly and rarely metastasize, but can be locally invasive if neglected or of an aggressive subtype. The local tissue destruction caused by an untreated BCC can be extensive, therefore optimal treatment should lead to tumour clearance. Surgery and topical medical treatments are successful therapeutic options for most superficial and nodular BCC. Systemic medical treatments may be considered when surgical procedures are not recommended on the basis of the anatomical site and tumor extension, and patients’ associated comorbidities. Expected cure rates and cosmetic outcome should be also carefully considered. A better understanding of the molecular mechanisms of BCC pathogenesis can lead to new developing target medical therapies, and data on their efficacy seem encouraging.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina